Business Context and Reporting Period
The filing is The Beauty Health Company’s unaudited Form 10-Q for the three months ended March 31, 2023. The company designs, manufactures, markets and sells aesthetic technologies and related products, including Hydrafacial, SkinStylus and Keravive. The filing issuer is identified as The Beauty Health Company, not “Skinhealth Systems Inc.”
The company reports one operating and reportable segment. Revenue is generated primarily from Delivery Systems and related Consumables.
Financial Performance and Position
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Net sales | $86.3 million | $75.4 million | +14.4% |
| Gross profit | $54.1 million | $50.9 million | +6.3% |
| Gross margin | 62.7% | 67.5% | Down 480 basis points |
| Loss from operations | $(17.3) million | $(14.0) million | Loss increased |
| Net income/(loss) | $(22.3) million | $31.5 million | Material decline |
| Basic loss/(earnings) per share | $(0.17) | $0.21 | Declined |
| Net cash used in operating activities | $(13.0) million | $(38.5) million | Improved |
Delivery Systems revenue was $45.4 million, up 8.9%, while Consumables revenue was $40.9 million, up 21.2%. Management attributed the sales increase primarily to stronger U.S. Consumables sales, increased Delivery System placements and the prior-year Syndeo launch.
Cost of sales increased 31.2% to $32.2 million. Gross margin was pressured primarily by charges for discontinued and obsolete products, as well as higher raw material, shipping and labor costs. Selling and marketing expense increased 6.3% to $38.7 million, research and development expense increased 4.8% to $2.3 million, and general and administrative expense increased 15.7% to $30.4 million.
Interest income was $4.3 million, primarily from money market investments. The company recorded a $9.1 million expense from the change in fair value of warrant liabilities, compared with $52.1 million of income in the prior-year quarter. This non-operating volatility was a major contributor to the year-over-year swing from net income to net loss.
Cash and cash equivalents were $532.3 million at March 31, 2023, compared with $568.2 million at December 31, 2022. Total assets were $995.0 million and total stockholders’ equity was $147.7 million. Inventories increased to $122.1 million from $109.7 million at year-end.
The company had $750.0 million principal amount of 1.25% convertible senior notes due 2026, reported at a net carrying value of $735.2 million. Its $50.0 million revolving credit facility, maturing in 2027, was undrawn, and the company stated that it was in compliance with all applicable covenants.
Material Changes Versus the Prior Comparable Period
- Revenue grew 14.4%, led by Consumables growth in the United States.
- Gross margin contracted from 67.5% to 62.7%, primarily because of discontinued and obsolete product charges and cost inflation.
- The company moved from $31.5 million of net income to a $22.3 million net loss. The comparison was also affected by a $52.1 million prior-year warrant-liability gain versus a $9.1 million current-year expense.
- Operating cash outflow improved to $13.0 million from $38.5 million, principally because of lower working-capital usage and noncash adjustments.
- Investing cash outflow increased to $21.7 million from $3.4 million, primarily because of $16.9 million paid for acquisitions.
- The company acquired Esthetic Medical Inc. in February 2023 for $11.8 million in cash and 109,625 shares of Class A common stock. It also acquired assets from Anacapa Aesthetics LLC in March 2023 and recognized approximately $5.0 million of intangible assets.
- The company revised prior-period financial statements for immaterial intercompany inventory-profit misstatements. The revision reduced December 31, 2022 inventory and stockholders’ equity by approximately $6.8 million and $7.1 million, respectively, and reduced Q1 2022 net income by $1.1 million.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide specific quantitative revenue or earnings guidance. Management stated that it expects to use available liquidity and operating cash flows to fund ongoing operations and growth for at least the next twelve months, while continuing to evaluate acquisitions, product launches, research and development, international expansion and capital needs.
- Management expects inflationary pressure on raw materials, shipping and labor costs to continue into the second quarter of 2023. Potential mitigation includes price increases and accepting revenue in U.S. dollars or local currencies, although these actions may not fully offset the impact.
- COVID-19-related store closures, travel restrictions and supply-chain challenges, particularly in China and other markets, may continue to cause uneven consumer traffic and a non-linear recovery.
- Industry consolidation or downsizing among medical, aesthetician and beauty-retail customers could adversely affect revenue and earnings.
- Cash balances may exceed FDIC insurance limits. The company stated that it had no accounts with Silicon Valley Bank or Signature Bank and experienced no direct loss from those failures.
- Hydrafacial has pending litigation against Ageless Serums involving alleged trademark, contract and patent claims. The parties reached a tentative settlement, but terms remained under negotiation and required bankruptcy-court approval.
- Hydrafacial is also pursuing patent-infringement claims against Cartessa Aesthetics; the parties were awaiting a decision on summary-judgment motions.
- The fair value of warrant liabilities increased to $24.6 million from $15.5 million at year-end, creating a $9.1 million quarterly expense.
Important Facts for Investors to Verify
- Confirm that the intended issuer is The Beauty Health Company, ticker SKIN, rather than Skinhealth Systems Inc.
- Assess whether revenue growth can be sustained while gross margin remains pressured by obsolete-product charges and inflation.
- Monitor cash burn, inventory growth and the company’s ability to fund operations and acquisitions without additional financing.
- Review the terms, conversion features and 2026 maturity of the $750.0 million convertible notes, as well as credit-facility covenant compliance.
- Evaluate the earnings impact and valuation volatility associated with warrant-liability remeasurement.
- Review the Esthetic Medical and Anacapa acquisitions, including contingent consideration, integration risks and expected contribution.
- Confirm the effect of the revised prior-period financial statements on trend analysis and comparability.
- Track the Ageless and Cartessa legal proceedings and any resulting settlement costs, damages or injunctions.